Taiwan
TCM Biotech 泰宗生技 is a biopharmaceutical company that is dedicated to innovation in the research and development of new therapeutics for liver disease. Their commitment is reflected in their focus on patent-layout and new drug development, addressing hepatitis B with prevention-TCM-800B combined with ETV, genetic detection through a ctDNA platform, and treatment options such as PTX-9908 combined with TACE for liver cancer and PTD-9908 combined anti-PD-1 treatment.
The company generates its main revenue from the sales of various medical products, including medicine, medical devices, and functional food. Additionally, TCM has obtained exclusive distribution rights for the Philips ventilator in Taiwan and has effectively leveraged its cross-strait medical channel for product sales and collaboration with Chinese partners to expand its business territory.
TCM Biotech, founded in 1998, envisions evolving into an international biotech company, continuously focusing on R&D, manufacturing, and marketing of new drugs for the prevention and treatment of liver disease. Emphasizing the advantages of its channels, product features, and competitive strength, the company aims to maximize revenue and profitability.
The company operates in the Biopharma and Biotechnology industries, and while specific headquarters location and latest investment details are not provided, TCM Biotech is positioned to make a significant impact in the field of liver disease treatment and prevention.
